Affiliation:
1. Internal Medicine Department, Hematology and Medical Oncology Division
2. Medical Education Department
3. Medical Doctor Program, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Abstract
Objective:
This review aimed to evaluate the effect of bevacizumab on adverse events and the quality of life (QoL) from colorectal cancer (CRC) patient.
Methods:
A literature search was conducted from PUBMED, MEDLINE databases and some valid literatures from another databases that published in the last 10 years, and the design is an observational and randomized controlled trial (RCT).
Results:
CRC is a malignancy, which happens in the colon or rectum. One of the therapy for CRC is by using bevacizumab, a monoclonal antibody. However, the usage of bevacizumab is still become a controversy because of its clinical complications. Several studies showed that bevacizumab could cause some adverse events in the cardiovascular, gastrointestinal, hematology, and others body systems and affect the CRC patient QoL. However, the clinical complication of this drug is also affected by the combination therapy regimen used.
Conclusions:
The use of bevacizumab could cause some adverse event in different aspects, including cardiovascular, gastrointestinal, hematology, and others. Some of those are significant, but others are not. Besides that, using bevacizumab as a treatment regiment could also affect the QoL of CRC patients, but it is also affected by the combination therapy regimen used.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference20 articles.
1. Colorectal cancer;Kuipers;Nat Rev Dis Prim,2015
2. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer;Mármol;Int J Mol Sci,2017
3. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;Van Cutsem;Ann Oncol,2016
4. Efficacy and safety assessment of the addition of bevacizumab to adjuvant therapy agents in cancer patients: a systematic review and meta-analysis of randomized controlled trials;Ahmadizar;PLoS ONE,2015
5. Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer;Kapelakis;Hell J Cardiol [Internet],2017
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献